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1038BK Virus Infection Is Associated with Hematuria
and Renal Impairment in Recipients of Allogeneic
Hematopoetic Stem Cell Transplants
Peter H. O’Donnell,1 Kate Swanson,1 Michelle A. Josephson,2 Andrew S. Artz,1
Sandeep D. Parsad,1 Charulata Ramaprasad,3 Kenneth Pursell,3 Elizabeth Rich,1
Wendy Stock,1 Koen van Besien1BK virus (BKV) is an important pathogen and cause of nephropathy in renal transplant recipients, but its sig-
nificance following hematopoetic stem cell transplantation (HSCT) is less well described. We measured
blood and urine BKV in 124 allogeneic HSCT patients (67 had undergone prior HSCT [surveillance cohort];
57 were monitored from transplant day 0 [prospective cohort]). BK viruria was manifest in 64.8% of the
patients; 16.9% developed viremia. In the prospective cohort, the median time from transplantation to BK
viremia development (128 days) was longer than for viruria (24 days; P\ .0001). Among clinical factors
(sex, disease, transplant type, alemtuzumab use, cytomegalovirus [CMV] viremia, graft-versus-host disease
[GVHD], donor HLA C7 allele), only CMV viremia was more common in patients with BKV infection
(P # .04). There was a direct relationship between blood and urine BKV levels and the occurrence, and
degree, of hematuria (P#.03). Finally, BKV infection was analyzed along with other clinical factors in relation
to the development of post-HSCTrenal impairment. On multivariate analysis, only BK viremia (P5.000002)
and alternative-donor transplantation (P5.002) were independent predictors of development of post-
HSCT renal impairment, with BK viremia associated with a median 1.62 mg/dL rise in creatinine from the
pretransplant baseline. Among 8 patients in the surveillance cohort with BK viremia, 2 developed biopsy-
proven BKV nephropathy requiring hemodialysis. Investigation of whether prophylaxis against, or treatment
of, BKV in the post-HSCT setting mitigates the associated morbidities, especially kidney injury, warrants
prospective evaluation.
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BK virus (BKV), a human polyomavirus [1], was
first recognized in 1971, after it was isolated from the
urine of a Sudanese renal transplant patient who was
hospitalized with acute renal failure and ureteral steno-
sis [2]. Most people are exposed to BKV during child-
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6/j.bbmt.2009.04.016Primary infectionoccurs at 4 to 5 years of age, andman-
ifests as a subclinical or nonspecific ‘‘flu-like’’ illness
[4,5]. BKV then establishes latency primarily in the
genitourinary tract [4,6], and viral reactivation gener-
ally occurs in immunocompromised patients [1,4].
BKV is an important pathogen and cause of ne-
phropathy in recipients of renal transplants. Kidney
transplant patients can become infected through reac-
tivation of latent virus, through primary infection
transmitted from the donor organ, or via blood trans-
fusion [3]. Importantly, BKV infection can transition
and escalate from viruria to viremia to nephropathy
[7]. BKV nephropathy (BKN) begins as a localized
viral presence in the tubular epithelial cells of the
kidney, and progresses to a diffuse and destructive
T cell-mediated interstitial nephritis [8]. The intersti-
tial infiltrate can cause scarring of the kidney paren-
chyma, loss of function, and kidney failure. Since
1995, an increase in BKN from 1% in 1995 to 5% in
2001 has been observed in renal transplant patients [9].
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transplantation (HSCT), the presence of BK viruria
has long been appreciated [10], and BKV has been im-
plicated in the pathogenesis of posttransplant hemor-
rhagic cystitis (HC) [10,11], although its exact role in
that situation remains unclear [12]. HC with docu-
mented BK viruria is commonly treated with i.v. cido-
fovir, a drug with considerable nephrotoxic and
myelosuppressive side effects [13]. Therefore, a better
understanding of the clinical importance of BK viruria
in the post-HSCT setting is needed. Furthermore,
although BKN has been documented in native kidneys
[5] and has recently been described in stem cell trans-
plant patients [14,15], the prevalence and clinical
importance of BK viremia and BKN inHSCT patients
have not been previously described. We hypothesized
that BKV infection is an important and underappreci-
ated pathologic phenomenon associated with hematu-
ria and the development of BKN in the post-HSCT
setting. For a period of 16 months, we systematically
monitored BKV infection in all allogeneic HSCT
recipients to better understand the potentially impor-
tant relationships between BK viruria, BK viremia,
hematuria, and BKN in these patients.MATERIALS AND METHODS
Study Participants
Beginning in September 2006, our transplant pro-
gram implemented routine monitoring of BKV in the
urine and blood of all adult patients who had already
undergone, or who were undergoing, an allogeneic
HSCT at the University of Chicago hospitals. All living
transplant patients who presented for medical care,
either as inpatients or outpatients, anytime after day
0 (their date of transplant), were monitored. Patients
were enrolled into the study when their first BKV level
(either urine or blood) was drawn.Data collection ended
on December 31, 2007. One hundred twenty-four pa-
tientsweremonitored. Sixty-seven hadundergone trans-
plant prior to September 2006 (the surveillance cohort);
57 underwent transplant between September 2006 and
December 2007, and were monitored from the time of
transplant (the prospective cohort). The data were ana-
lyzed in the spring of 2008. Institutional review board
approval was received for analysis of the data.Monitoring Methods and Data Included
for Analysis
At any presentation to the University of Chicago
Transplant Program formedical care during the period
of study monitoring, HSCT patients submitted blood
and urine samples for BKV detection and quantifica-
tion. The frequency of sampling depended on how of-
ten the patient was seen. Typically, during a singleinpatient stay, only 1 set of BKV samples (blood and
urine) was collected, unless the patient had new hema-
turia later in the hospital stay. Blood and urine BKV
samples were also collected at every outpatient visit.
Patients were typically seen at least weekly until day
100 after transplant, at least every month until 6
months after transplant, at least 6 times between 6
months and 24 months after transplant, and at least
once per year thereafter. The clinical data that were
routinely captured from each inpatient or outpatient
visit, when available, included: graft-versus-host disease
(GVHD) assessment, microscopic urinalysis (U/A)
results to measure urinary red blood cell (RBC) count,
serum creatinine, blood tacrolimus level, and blood cy-
tomegalovirus (CMV) status. Supportive care and
infection prophylaxis at the University of Chicago
transplant center have been previously described [16].
BKV Polymerase Chain Reaction (PCR) Analysis
Quantitative PCRwas performed at the University
of Chicago hospital laboratories on blood and urine
samples to detect BKV DNA. Samples were placed
in lysis buffer and stored at 270C until processed.
Using 200-mL aliquots of whole blood (in EDTA) or
urine, DNA extraction was performed on the Roche
MagNA Pure instrument (Roche Diagnostics, Indian-
apolis, IN), using the Roche Total NA kit, eluted into
a final volume of 50 mL. In each extraction run, 2
different known concentrations of positive control
containing targetDNAwere processed as well as a neg-
ative control containing bacterial DNA.
Mastermix was prepared using theRoche FastStart
Plus kit, and primers and probes were purchased from
TIB MolBiol (Berlin, Germany). We used a multiplex
assay for BK and JC viruses. The BKV target is the
gene for large T antigen. To 5 mL of patient eluate
was added 15 mL of master mix, and the samples were
runon aRocheLightCycler 1.2.Theprotocol included
45 cycles of PCR. Five dilutions of a stock solution of
cloned target DNA were used to generate a standard
curve to determine the absolute quantification of
DNA present in positive samples. Based on the
standard curve, quantification was reported in a range
from 2500 to 25,000,000 copies/mL of patient sample;
positives outside the range are reported as.25,000,000
or\2500. The detection limit for the assay was vali-
dated as equivalent to 500 copies/mL of patient sample
(10 copies/reaction). For positive samples, melting
curve analysis was performed to verify the amplified
product. An internal control was added to confirmneg-
ative samples.
Statistical Methods
The following variables were evaluated for their
association with BK viruria and BK viremia: recipient
sex, donor type, diagnosis, presence or absence of
Table 1. Clinical and Transplant Characteristics of the 124
Patients and of the Prospective Cohort
Patient Demographics Entire Study Group
Prospective
Cohort
Number of patients 124 57
Median age (range) 49 (17-72) 52 (18-71)
Male 76 (61.3%) 38 (66.7%)
Female 48 (38.7%) 19 (33.3%)
Year of transplant
1998-2002 14 (11.3%) 0 (0.0%)
2003-August 2006 54 (43.5%) 4 (7.0%)
September 2006-December 2007 56 (45.2%) 53 (93.0%)
Transplant donor
HLA-identical 70 (56.5%) 29 (50.9%)
Matched-related 66 (53.2%) 27 (47.4%)
Syngeneic 4 (3.2%) 2 (3.5%)
Alternative 54 (43.5%) 28 (49.1%)
Matched-unrelated 36 (20.0%) 18 (31.6%)
Mismatched-related 2 (1.6%) 0 (0.0%)
Mismatched-unrelated 6 (4.8%) 4 (7.0%)
Cord 10 (8.0%) 6 (10.5%)
Primary disease
CML 8 (6.5%) 1 (1.8%)
CLL 5 (4.0%) 2 (3.5%)
AML 50 (40.3%) 25 (43.8%)
ALL 8 (6.5%) 2 (3.5%)
MDS 9 (7.3%) 4 (7.0%)
Aplastic anemia 3 (2.4 %) 1 (1.8%)
Non-Hodgkin lymphoma 27 (21.8%) 16 (28.0%)
Hodgkin lymphoma 5 (4.0%) 3 (5.3%)
Multiple myeloma 3 (2.4%) 1 (1.8%)
Amyloidosis 1 (0.8%) 1 (1.8%)
Waldenstrom’s 1 (0.8%) 0 (0.0%)
Myelofibrosis 1 (0.8%) 0 (0.0%)
Pure red cell aplasia 1 (0.8%) 0 (0.0%)
PNH 1 (0.8%) 0 (0.0%)
Plasmacytoid dentritic cell tumor 1 (0.8%) 1 (1.8%)
Conditioning regimen
Fludarabine/melphalan/alemtuz 62 (50.0%) 26 (45.6%)
Fludarabine/busulfan/alemtuz 21 (16.9%) 13 (22.8%)
TBI/etoposide 9 (7.2%) 2 (3.5%)
Clofarabine/melphalan/alemtuz 8 (6.5%) 6 (10.5%)
Fludarabine/melphalan/ATG 5 (4.0%) 2 (3.5%)
TBI/fludarabine/thiotepa/ATG 4 (3.2%) 3 (5.3%)
TBI/cyclophosphamide 4 (3.2%) 0 (0%)
TBI/fludarabine/thiotepa 3 (2.4%) 2 (3.5%)
Fludarabine/cyclophosphamide 3 (2.4%) 1 (1.8%)
BEAM 1 (0.8%) 0 (0%)
Busulfan/cyclophosphamide 1 (0.8%) 0 (0%)
Melphalan 1 (0.8%) 1 (1.8%)
TBI/etoposide/alemtuz 1 (0.8%) 1 (1.8%)
TBI/fludarabine 1 (0.8%) 0 (0%)
Graft-versus-host disease
Acute graft-verus-host disease,
grade II-IV
40 (32.0%) 14 (24.6%)
Any graft versus host disease 67 (54.0%) 23 (40.4%)
CMV viremia
CMV viremia at any time
posttransplant
26 (21.3%) 16 (28.6%)
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; AML, acute myelogenous leukemia; ALL, acute lymphocytic
leukemia; MDS, myelodysplastic syndrome; PNH, paroxysmal nocturnal
hemoglobinuria; TBI, total body irradiation; alemtuz, alemtuzumab;
ATG, antithymocyte globulin; BEAM, carmustine, etoposide, cytarabine,
and melphalan.
The clinical characteristics of the 57 patients enrolled from day 0 of their
transplant (the prospective cohort) were not statistically different from
those of the entire study group.
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imen, presence of CMV viremia at any time during the
monitoring period, and donor HLA C7 allele status.
Donor HLA C7 allele status was included based
upon evidence in renal transplant patients that absence
of the HLA C7 allele in the donor is associated with
development of BK viremia in the recipient [17].
To evaluate the potential effect of BK viruria or
BK viremia on hematuria, hematuria was defined as
absent, trivial (\3 RBC/high-power field [hpf] on uri-
nalysis), or clinically significant ($3 RBC/hpf). For
each patient, correlation between hematuria and the
median as well as the maximum level of BKV in the
urine was investigated. The median level of BKV was
the median of all samples obtained in an individual pa-
tient. The maximum concentration was the highest
level measured in each individual patient. We also
evaluated the correlation between presence of BK vire-
mia at any time posttransplant and the occurrence of
hematuria.
To evaluate the potential effect of BK viruria or
viremia on kidney function, wemeasured the creatinine
increment in eachpatient.Thiswas defined as thediffer-
ence between the serum creatinine at the time of trans-
plant and the highest creatinine observed during the
time of monitoring. We then evaluated the association
between creatinine increment and the following factors:
recipient sex, diagnosis, donor type, presence of acute or
chronicGVHD (aGVHD, cGVHD) at any time during
the monitoring period, use of alemtuzumab in the con-
ditioning regimen, presence of CMV viremia at any
timeduring themonitoringperiod, presence of hematu-
ria at any time during the monitoring period, presence
of BK viruria at any time during the monitoring period,
presence of BK viremia at any time during the monitor-
ing period, and donor HLA C7 allele status. Post-
HSCT tacrolimus levels and their potential impact on
creatinine changes were also considered in the analysis
of each clinical variable’s effect.
Univariate statistical comparisons between patients
based on the clinical factors of interest were analyzed
using the Student t-test. All P values are 2-sided. The
multivariate analysis of predictors of renal function dec-
rement used multiple regression, with stepwise back-
ward-elimination variable selection [18]. All covariates
that were significant with a P value\.05 in the univar-
iate analysiswere retained in an initial regressionmodel.
(Because all patients with BK viremia also had BK viru-
ria, and to determine whether BK viruria itself was an
independent predictor, BK viruria in the absence of
BK viremia was incorporated as its own covariate in
the regressionmodel, and BK viremia was incorporated
as a separate covariate.) Factors not statistically signifi-
cant (P$ .05) were removed from themodel 1 at a time,
with a reestimationof allmodel variables after each step.
Variable elimination (or reinsertion) was stopped when
all remaining factors were significant at P \ .05.Because of multiple comparisons in the multivariate
analysis, we considered only P values\.01 as statisti-
cally significant.
Table 2. Measure of theDegree toWhichBKV Infection Status Changes for Individual Patients over Time in the post-HSCTPeriod
n Median BKV Level (copies/mL)
Median Duration
of Observation (days)
Median Duration
of Positivity (days) Median No. of Samples Tested
BK Viruria
Persistently positive 27 25,000,000 (13,500-25,000,000) 157 (16-532) 157 (16-532) 11 (2-44)
Variable 52 2,500 (0-25,000,000) 322 (1-441) 32 (1-411) 11 (1-47)
Persistently negative 43 0 (0-0) 188 (1-429) 0 (0-0) 5 (1-21)
BK viremia
Persistently positive 2 1,147,250 (228,000-2,066,500) 286 (194-378) 286 (194-378) 22 (10-35)
Variable 19 0 (0-133,000) 220 (60-427) 1 (1-42) 17 (5-37)
persistently negative 103 0 (0-0) 213 (1-532) 0 (0-0) 9 (1-47)
BKV indicates BK virus; HSCT, hematopoietic stem cell transplantation.
Approximately one-quarter of all patients were persistently positive for BKV in the urine, whereas most fluctuated between exhibiting low-level positive
and negative urine samples with a usual duration of positivity of approximately 1 month. In contrast, when BK viremia occurred it was almost always at
low levels and was transient or intermittent. Only 2 patients had persistent BK viremia for the duration of the observation period. Notes: persistently
positive patients were those who had 2 or more samples collected, and all samples were positive. Variable patients produced both positive and negative
samples during the observation period, or they produced one positive sample and then had no other samples drawn. Persistently negative patients never
exhibited a positive sample. In patients who had more than one period of viral positivity, the longest period was used to calculate the cohort median. Two
patients did not have urinary BKV measured post-HSCT.
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Patient Characteristics
Theclinical characteristics of the entire study cohort
as well as the prospective cohort are summarized in Ta-
ble 1. The entire cohort included patients undergoing
HSCT as early as 1998, although the large majority
was transplanted after 2002. The median age of partici-
pants at the time of their transplant was 49 years, and
61.3% of patients were males. Many diagnoses were in-
cluded, but the predominant underlying diseases were
acute myelogenous leukemia (AML) in 40.3% and
non-Hodgkin lymphoma in 21.8%.Themajority of pa-
tients (n5 70, 56.5%) received cells fromanHLA-iden-
tical donor, defined as a matched-related (n5 66) or
syngeneic donor (n5 4); the remainder received alter-
native-donor transplants, defined as matched-unrelated
(n5 36), mismatched-related (n5 2), mismatched-
unrelated (n5 6), cord (n5 4), or haploidentical/cord
(n5 6) donors. Most patients (n5 90, 72.6%) received
conditioning regimens that included alemtuzumab,
which is routinely used at our transplant center. Some
form of GVHD (aGVHD and/or cGVHD) was diag-
nosed in 67 patients (54.0%), with 40 patients0 50 100 150 200 250
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Figure 1. Cumulative incidence and timing of development of BK viru(32.0%) manifesting aGVHD (grade II-IV). In our
study, 61 patients had donors lacking the HLA C7 al-
lele (whereas, in another 18/124 patients, the donor
HLA C7 status was unknown; 1 additional patient re-
ceived a haploidentical/cord transplant in which only
1 of the donor sources lacked HLA C7). CMV viremia
was detected in 26 of 122 patients (21.3%) during the
monitoring period.
The clinical characteristics of the 57 patients
enrolled from day 0 of their transplant (the prospective
cohort) were reflective of (and not statistically different
from) the entire study group with respect to age, sex,
predominant underlying diseases, transplant type, use
of alemtuzumab, GVHD, donor HLAC7 allele status,
and CMV viremia prevalence (see Table 1).
Prevalence and Timing of Onset of BKV
Infection
In the entire cohort, themedian time afterHSCT to
first virus sampling was 58 days (range: 1-3196 days),
and the median time to last follow-up virus sampling
was454days (range: 3-3554days). Seventy-ninepatients
(64.8%) had BK viruria at some time duringmonitoring
post-HSCT. The remainder (43/1225 35.3%) never300 350 400 450 500 550
BK Viruria
BK Viremia
 transplant
ria and viremia for the prospectively monitored cohort (n5 57).
Table 3. Association between Various Clinical Factors and
Prevalence of BK Viruria and Viremia
Clinical Factor
BK Viruria BK Viremia
n (%) P n (%) P
Females 28/46 (61%) .48 12/48 (25%) .06
Males 51/76 (67%) 9/76 (12%)
HLA identical donor 41/71 (58%) .09 8/71 (11%) .06
Alternative donor 38/51 (75%) 13/53 (25%)
CML 6/8 (75%) .77 2/8 (25%) .53
CLL 2/5 (40%) .12 0/5 (0%) .30
AML 30/49 (61%) .50 9/50 (18%) .79
ALL 7/8 (88%) .27 2/8 (25%) .53
MDS 6/9 (67%) .90 1/9 (11%) .63
AA 2/3 (67%) NT 0/3 (0%) NT
NHL 20/26 (77%) .14 5/27 (19%) .80
HD 4/5 (80%) .47 1/5 (20%) .85
MM 1/3 (33%) NT 0/3 (0%) NT
Alemtuzumab 61/90 (68%) .24 16/90 (18%) .68
No alemtuzumab 18/34 (53%) 5/34 (15%)
GVHD 34/67 (51%) .72 8/67 (12%) .47
No GVHD 45/57 (79%) 13/57 (23%)
Donor HLA C7 positive* 32/44 (73%) .41 9/44 (20%) .75
Donor HLA C7 negative* 42/61 (69%) 11/61 (18%)
CMV viremia† 24/26 (92%) .001 8/26 (31%) .04
No CMV viremia† 5/96 (5%) 13/96 (14%)
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; AML, acute myelogenous leukemia; ALL, acute lymphocytic
leukemia; MDS, myelodysplastic syndrome; AA, aplastic anemia; NHL,
non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma.
NT, not tested; GVHD, graft-versus-host disease.
Only occurrence of CMV viremia at any time posttransplant was signif-
icantly associated with an increased risk of also having BK viruria
(P5.001) and BK viremia (P5.04). Within disease subcategories, P
values reflect the comparison between patients with the listed disease
and all other patients in the study. For 2 patients in the study, urine sam-
ples for BK were not obtained, thus the n denominator for some clinical
factors is different between the BK viruria and BK viremia columns.
*For donor HLA C7 allele status, information was not available for 18
patients, and 1 patient received a haploidentical/cord transplant in which
only 1 of the donor sources was positive for the HLAC7 allele—this pa-
tient was not included in the above table.
†For the presence of CMV viremia, 2 patients did not have blood CMV
samples drawn.
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low-up. Two patients did not have urinary BKV mea-
sured post-HSCT (both died shortly after transplant,
precluding obtainment of samples; neither had oligu-
ria/anuria nor renal failure). Twenty-one patients
(16.9%) had BK viremia detected at some time during
monitoring. The remainder (103/1245 83.1%) never
demonstrated BKV in the blood post-HSCT.
Approximately one-quarter of all patients were
persistently positive for BKV in the urine, whereas
most others fluctuated between exhibiting low-level
positive and negative urine samples with a usual dura-
tion of positivity of approximately 1 month (Table 2).
In contrast, when BK viremia occurred, it was almost
always at low levels and was transient or intermittent.
Only 2 patients had persistent BK viremia for the
duration of the observation period.
In the prospective cohort, the median time to first
virus sampling was 20 days (range: 1-34 days), and the
median time to last virus sampling was 146 days (range:
3-454 days). Among these patients, 40 (72.7%) devel-
oped BK viruria and 13 (22.8%) developed BK viremia.
In this group, the median time from transplantation to
development of BK viruria was 24 days (range: 3-138
days), whereas BK viremia occurred at a significantly
longer median time of 128 days (range: 62-307 days)
(P\ .0001). The cumulative incidence and timing of
development of BK viruria and viremia for the prospec-
tive cohort are depicted in Figure 1.
Clinical Factors Having an Impact on BKV
Infection
Because previous studies have suggested that in-
creased age is associated with an increased prevalence
of BK viruria, at least in immunocompetent popula-
tions [19,20], we analyzed the median age of our
patients who had BK viruria and compared it to the
median age of our patients without urinary BKV.
The median age of the 2 groups was not statistically
different (BK viruria group5 48 years, no urinary
BKV group5 52 years, P5 .07).
In a univariate analysis of all of the clinical factors
examined, only CMV viremia was significantly associ-
ated with an increased risk of also having BK viruria
(P5 .001) and BK viremia (P5 .04) (Table 3). Nota-
bly, BK viruria and viremia were not more prevalent
in patients receiving alemtuzumab.
Relationship Between BKV Infection
and Hematuria
One hundred twenty of the 124 study patients had
at least 1 U/A performed. Only 19 patients (15.8%)
never demonstrated microscopic hematuria at any
time (‘‘no hematuria group’’). Most patients with
microscopic hematuria had trivial hematuria (n5 84/
101). Seventeen patients had clinical hematuria.The dichotomous presence or absence of BK viru-
ria in the post-HSCT period was not a predictor of
development of hematuria, because there was no dif-
ference in the prevalence of BK viruria in those who
demonstrated hematuria compared to those who did
not. There was, however, a significant association be-
tween the median amount of BK viruria and the degree
of hematuria. The average of all patients’ median BK
viruria levels was 1.99(106) copies/mL in the ‘‘no he-
maturia’’ group, lower than the average of the median
BK viruria levels in the ‘‘trivial hematuria’’ group
(5.44(106) copies/mL, P5 .06), which in turn, was sig-
nificantly lower than the average of the median BK
viruria levels in the ‘‘clinical hematuria’’ group
(13.32(106) copies/mL, P5 .03) (Figure 2). This sug-
gests that there is a direct relationship between the
median amount of urinary BKV in the post-HSCT
period and both the presence, and the degree, of
microscopic hematuria.
Median of Urinary BKV Levels Maximum Urinary BKV Level
0
1.0×107
2.0×107
3.0×107
P=0.063
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Figure 2. Relationship between both median (left panel) and maximum (right panel) levels of urinary BKV and degree of microscopic hematuria post-
HSCT. A direct relationship was seen between higher median and maximum levels of urinary BKV with greater amounts of microscopic hematuria.
RBC5 red blood cells.
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imum urinary BKV level of 5.27(106) copies/mL,
which was not significantly different than that of those
with trivial hematuria (8.44(106) copies/mL, P5 .25).
Yet, both groups’ levels were significantly lower than
the maximum BK viruria levels of those with clinical
hematuria (17.65(106) copies/mL, P\.007) (Figure 2).
These data suggest that maximum BKV urinary load,
even as measured by 1 U/A, is directly associated with
both the occurrence, and the degree, of hematuria.
We also examined whether BK viremia was associ-
ated with hematuria. In our study, interestingly, all 19
patients without hematuria were BK blood negative,
whereas 21 of 101 patients with hematuria were BK
blood positive (P5 .03).Impact of BKV Infection on Renal Function
Nearly all transplant patients were observed to in-
cur a decrement in renal function simply by undergoing
HSCT. The median baseline (day 0) serum creatinine
value for the entire cohort was 0.80 mg/dL. This was
significantly lower than the median of the peak post-
HSCT creatinine values for the cohort, 1.30 mg/dL
(P\10212). Of the 124 patients, only 12 did not have
higher maximal post-HSCT creatinine values com-
pared to their day 0 creatinine baselines.
On univariate analysis, 6 clinical factors were asso-
ciated with a concomitant decrement in renal function:
female sex, having undergone an alternative-donor
transplant, having an underlying disease that was not
myelodysplastic syndrome (MDS), having CMV vire-
mia, having BK viruria, and having BK viremia (Table
4). Median post-HSCT tacrolimus levels for patients
with these characteristics were not significantly higher
and did not explain any of these associations. On
multivariate analysis, only 2 factors were independently
associated with a significant change in creatinine:undergoing an alternative-donor transplant (P5 .002)
and having BK viremia (P5 .000002). The factor with
the greatest absolute effect on creatinine elevation was
BK viremia: the creatinine rise was 1.62 mg/dL in pa-
tients with BK viremia, but only 0.64 mg/dL in those
without BKV in the blood (P5 .001) (Figure 3).Development of BKV Nephropathy
Among the 8 patients in the surveillance cohort
with BK viremia, 2 developed biopsy-proven BKV-as-
sociated interstitial nephritis with severe renal failure.
No other cases of unexplained renal failure requiring
kidney biopsy occurred. Interestingly, the 2 patients
with BKV nephropathy were the only 2 to have persis-
tently positive blood BKV levels throughout the
period of monitoring (Table 2). A description of these
2 cases of BKV nephropathy is provided here.
The first patient was a 36-year-old female with
relapsed Hodgkin disease (HD) who had previously un-
dergone an autologous HSCT 1 year prior. Her condi-
tioning regimen prior to matched, unrelated donor
transplantation consisted of fludarabine (Flu), melpha-
lan (Mel), and alemtuzumab. She had no prior history
of kidney disease. Transplant was complicated with ste-
roid-dependent GVHD. Her renal function began to
slowly decline after transplant. BK viremiawas detected,
and without another cause of her renal insufficiency
identified, a kidneybiopsywas performed9months after
transplant. The biopsy revealed changes reflective of
polyomavirus nephropathy: a diffuse, prominent, inter-
stitial inflammatory reaction with tubulitis (Figure 4A).
These cells tested strongly positive using an SV40 im-
munohistochemical stain (SV40 andBKV share a signif-
icant region of homology) [21] (Figure 4B). Urinary
BKV levels were consistently at the upper limit of the
assay’s detection throughout this period, whereas blood
BKV levels were modestly and consistently elevated.
Table 4. Average Creatinine Rise Post-HSCTas a Function of
Various Clinical Factors
Risk Factor n
Creatinine
Rise (mg/dL)
Creatinine
Rise of
Comparison
Group (mg/dL) Difference
P
Value
Female sex 48 1.02 0.67 +0.35 .04
Alternative-donor 54 1.10 0.58 +0.52 .0009
CML 8 0.71 0.81 20.10 .67
CLL 5 0.88 0.80 +0.08 .60
AML 50 0.96 0.70 +0.26 .12
ALL 8 1.01 0.79 +0.22 .41
MDS 9 0.47 0.83 20.36 .02
NHL 27 0.60 0.86 20.26 .07
HD 5 1.42 0.78 +0.64 .46
Hematuria 101 0.87 0.62 +0.25 .26
Alemtuzumab 90 0.81 0.78 +0.03 .93
GVHD 68 0.90 0.69 +0.21 .17
Donor HLA C7
positive
45 0.93 0.78 +0.15 .41
CMV viremia 26 1.21 0.70 +0.51 .03
BK viruria 79 0.97 0.53 +0.44 .001
BK viremia 21 1.62 0.64 +0.98 .001
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; AML, acute myelogenous leukemia; ALL, acute lymphocytic
leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lym-
phoma; HD, Hodgkin disease; MM, multiple myeloma; GVHD, graft-ver-
sus-host disease; CMV, cytomegalovrius.
For each clinical factor listed, the comparison group is comprised by all
patients not demonstrating that clinical characteristic (eg, for ‘‘females,’’
the comparison group is all males; for ‘‘HLA alternative’’ the comparison
group is all patients who received an HLA-identical transplant; for ‘‘BK
viremia’’ the comparison group is all patients without BK viremia; for
the disease subtypes, the comparison group is all other patients in the
study who did not have that disease). Patients with aplastic anemia
(n5 3), myeloma (n5 3), and 1 of the 6 other singularly represented
diseases (n5 6) were not tested because ofthe small sizes of these sub-
categories. On univariate analysis, 6 of the above clinical factors were
significantly associated with a concomitant decrement in renal function:
female sex; having undergone an alternative-donor transplant; having an
underlying disease that was not MDS; having CMV viremia; having BK vi-
ruria; and having BK viremia. Patients with MDS had a significantly
smaller rise in creatinine (0.47 mg/dL) than all other patients (0.83 mg/
dL, P5.02). On multivariate analysis, only 2 factors were independently
associated with a significant change in creatinine: undergoing an alterna-
tive-donor transplant (P5.002) and having BK viremia (P5.000002).
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modulatory agent, but there was no appreciable decre-
ment in her blood or urine BKV levels, and her
glomerular filtration rate continued to worsen. She
required initiation of hemodialysis 18 months after her
transplant.
The second patient was a 41-year-old female with
AML who underwent matched-unrelated donor
HSCT in first remission after Flu/Mel/alemtuzumab
conditioning. Two and a half years after her transplant,
she began to develop acute renal insufficiency, which
corresponded temporally to a rapid spike in her blood
BKV measurements to very high levels. Urinary BKV
levels were also consistently at the upper limit of the
assay’s detection. An alternative cause of her acute re-
nal insufficiency was not found. Leflunomide was
given, without a dramatic decrease in blood or urine
BKV levels. Kidney biopsy revealed polyomavirus ne-phropathy (Figure 4C). Renal deterioration continued
and the patient ultimately required hemodialysis.
The temporal relationship between the timing and
magnitude of BK viremia and creatinine rise in these 2
patients is shown in Supplemental Figure S1.DISCUSSION
The result of this analysis of a large, systematically
monitored cohort of patients demonstrates that BK
viruria is a common finding among HSCT recipients,
whereasBKviremia is less common,but not rare. BKvi-
ruria is detectable early after HSCT, and, in the cohort
of patients who were tracked from day 0, the timing of
detection of BK viruria (24 days) was similar to the me-
dian timing of first virus sampling (20 days), suggesting
that BK viruria may actually be detectable even earlier,
and, in a portion of patients, is likely present at baseline
(pretransplant).Althoughwedidnotmeasure this, BKV
shedding can be detected in the urine of a portion of im-
munocompetent individuals [22,23] and, in a recent
preliminary analysis, was detected in 46% of transplant
patients pretransplant [24]. The prevalence of post-
HSCT BK viruria in our study (64.8%) is similar to
multiple other studies that have demonstrated rates
between 50% and 100% [25-29].
In contrast, BK viremia has been less well-studied,
and its timing of detection in our post-HSCT popula-
tion was significantly later than that of BK viruria,
suggesting that BK viremia represents a separate, path-
ologic disease state in this patient population. Several
hypotheses have been purported [3] in kidney trans-
plant recipients, whichmay explain the late occurrence
of BK viremia in our patients: BKV may be acquired
via blood transfusions (a risk that would increase
over time in patients because of the chronologic, cu-
mulative need for transfusions post-HSCT); it could
represent acquisition of BKV from the donor, with
a period of latency or required replication post-
HSCT until detection is possible; or it may represent
a form of native ‘‘progression’’ of BKV infection in
the transplant recipient, possibly in a step-wise manner
(genitourinary BKV latency/ detectable BK viruria
/ frank BK viremia) [7,9,14,30,31]. Our study did
not measure BKV in the blood of donors, nor does
our hospital routinely screen for BKV in transfused
blood products, so we could not definitively differenti-
ate between these possibilities in our study. However,
the fact that all patients who had BK viremia also had
BK viruria, and the fact that BK viruria is detectable
much earlier, lends credence to the ‘‘progression’’
hypothesis.
Analysis of several transplant-related clinical fac-
tors potentially associated with the development of
BKV infection was undertaken in this study, but none
of the common predictors of transplant-related
BKV blood negative BKV blood positive
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Figure 3. Impact of BK viremia on change in creatinine post-HSCT. Change in creatinine represents the difference between the maximum post-HSCT
creatinine level and the pretransplant baseline creatinine. BK viremia was the factor having the greatest absolute effect on creatinine elevation in this
study: the creatinine rise was 1.62 mg/dL in patients with BK viremia, but only 0.64 mg/dL in those without BKV in the blood (P5.001).
Biol Blood Marrow Transplant 15:1038-1048, 2009 1045BK Virus Morbidity Post-transplantoutcomes was associated with an increased (or de-
creased) occurrence of BK viruria or viremia. Having
GVHD and undergoing an HLA-mismatched trans-
plant had specifically been previously implicated as
possible risk factors for BKV reactivation [25,32], but
these associations were not found in our study. Only
CMV viremia was found to be associated with higher
rates of BK viruria and viremia. One prior case report
also suggested a potential correlation between CMV
and BKV reactivation [33]. Although causation cannot
be determined by our data, we do not believe thatCMV
viremia predisposes a patient to the development of
BKV infection. Rather, it is more likely that the as-
yet-poorly defined factors that control CMV reactiva-
tion/replication in patients in the post-HSCT period
are the same factors that govern this process for BKV.
Our data add supporting evidence to prior studies
that have implicated urinary BKV in the development
of post-HSCT hematuria [11]. Our findings that both
a higher continuous level of urinary BKV and a higher
maximum urinary BKV level are associated with
greater numbers of RBC in the urine are consistent
with prior similar associations [28,29,34,35]. Although
we did not assess the clinical severity of episodes of
hematuria (i.e., whether there were associated urinary
symptoms), our data do support the hypothesis that
higher levels of urinary BKV may be correlated with
greater urinary bleeding. Our finding of an association
between BK viremia and hematuria was consistent
with findings from 2 prior studies [36,37], but in
contrast to another report that found no correlation
[28]. Given that hematuria (and HC) are problematic
and potentially serious HSCT complications [38],our data would support prospective testing of the con-
cept that pharmacologic reduction in urinary BKV
load, if achievable, might prevent more severe cases
of urinary bleeding as can be seen with severe HC.
The most intriguing conclusion from this study
was the demonstration of BK viremia as an indepen-
dent risk factor for deterioration of renal function in
the post-HSCT setting. Previously, only case reports
had described an association between BKV and renal
failure post-HSCT [14,15,39,40]. Although HSCT it-
self resulted in an aggregate rise in creatinine above
pretransplant baselines in our study, undergoing an al-
ternative-donor transplant and having BK viremia
emerged as being independently associated with a sta-
tistically significant increase beyond the increase seen
with transplantation alone. The absolute increase in
creatinine observed in patients with BK viremia (me-
dian 1.62 mg/dL) was large, and had the strongest
statistical association. Even in the absence of frank
oliguric renal failure, this degree of rise in serum cre-
atinine represents a significant decrement in glomeru-
lar filtration rate, which can complicate the ongoing
treatment of patients especially as it has an impact on
clearance of many transplant-related medications, pre-
cludes contrast-related radiologic imaging, and com-
plicates handling of fluid volumes accompanying
intravenous medications and blood products.
In contrast to BK viruria, which often persisted dur-
ing the period of observation, BK viremia was transient
inmany cases and sowereelevations increatinine.Still, 2
of 8 patients in the surveillance cohort (which represents
the patientswith prolonged follow-up) developed severe
interstitial nephritis that was biopsy-proven as BKV
Figure 4. Photomicrographs of the pathologic findings in 2 patients
with biopsy-proven BK virus-induced nephropathy. (A) (top panel)
High-powered view of enlarged tubular epithelial cells showing viral cy-
topathic effect and intranuclear inclusions in 1 of the 2 affected patients
in our study. Glomeruli and vascular structures are normal; (B) (middle
panel) SV40 immunohistochemical stain further demonstrating the
intranuclear viral inclusions in the same patient (SV40 and BKV share
a significant region of homology); (C) (bottom panel) similar pathologic
findings in the kidney of the second patient in our study with BKV
nephropathy.
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to have persistently positive blood BKV levels in our
study, this may suggest that prolonged duration of BKviremia is a risk factor for developingBKVnephropathy.
It is also likely that at least some of the other patients in
our studywith impairment of renal functionhadundiag-
nosed mild BKV nephropathy [14,15]. Thrombotic
thrombocytopenic purpura (TTP)-associated renal fail-
ure was not a confounder of the BK viremia-renal im-
pairment association, as only 2 patients developed
TTP in our study and neither had BK viremia. In a por-
tion of the caseswithBKviremia (10 of 21, including the
2patientswithbiopsy-provenBKVnephropathy and re-
nal failure), the occurrence of renal impairment tempo-
rally followed the patient turning positive for blood
BKV or a spike in blood BKV levels, suggesting a direct
causative relationship. In the other BK viremic patients,
no clear temporal relationship between the timing of vi-
remia and creatinine rise was observed, and the inciting
event causing acute renal impairment was likely another
cause. In these cases where BK viremia itself was not di-
rectly causative of renal impairment, it is possible that
the predisposing factors for renal impairment—perhaps
in the local microenvironment of the kidney itself—are
the same, which predispose to BKV reactivation and
BK viremia, thereby explaining the strong association
that was found.
One limitation of this study is that we were not able
to account for all differences that may have existed in
the administration of all potentially nephrotoxic con-
comitant medications post-HSCT, although we did
control for tacrolimus, perhaps the most commonly
used nephrotoxic agent in our patients. Although al-
most all patients at our center are treated with the
same prophylactic medical regimens post-HSCT, pa-
tient-specific differences in the use of other chronic
medications were not accounted for in our analysis.
The use of aminoglycosides is specifically avoided in
our transplant population in usual practice, and ami-
noglycosides were not administered to either of the 2
patients who ultimately developed renal failure requir-
ing hemodialysis. In considering the impact of condi-
tioning regimens on our outcomes, use of total body
irradiation (TBI) and/or cyclophosphamide (Cy) did
not have an impact on creatinine change.We also eval-
uated whether the use of alemtuzumab, a potent immu-
nosuppressant [41,42], which is favored at our center,
had an impact on the incidence or severity of BK viruria
or viremia. Importantly, BKV infection was not in-
creased in patients receiving alemtuzumab. Separately,
we cannot rule out the possibility that some patients
had more frequent virus sampling because of unmea-
sured variables, such as increased posttransplant com-
plications. Finally, this study was conducted at 1
urban transplant center, and transplant-related sup-
portive carepractices thatwerenot captured inour anal-
ysis are not necessarily similarly implemented at other
centers.
In summary, BKV infection is common in post-
HSCT patients, is associated with hematuria, and
Biol Blood Marrow Transplant 15:1038-1048, 2009 1047BK Virus Morbidity Post-transplantBK viremia, possibly by causing kidney damage that
can lead to BKV nephropathy in some cases, is an in-
dependent risk factor for worsening renal function in
the post-HSCT period. Investigation of whether pro-
phylaxis against, or treatment of, BKV in the post-
HSCT setting mitigates the associated morbidities,
especially kidney injury, is the subject of ongoing
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Supplemental Figure S1. Relationship between timing andmagnitude of BK viremia and creatinine rise in the 2 patients who had persistently positive
blood BKV levels and who developed BKV nephropathy and end stage renal failure. (A) (top panel) corresponds to the first patient described in the text;
(B) (bottom panel) corresponds to the second patient described in the text.
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